Clorox offers an asymmetric recovery profile as Purell, ERP normalization and margin repair support re-rating from a depressed 15.5x P/E.
The Clorox Company is a leading multinational manufacturer and marketer of consumer and professional products, operating a highly diversified portfolio with a history spanning over 112 years [cite: 1, 2]. The company operates through four primary business segments: Health and Wellness, Household, Lifestyle, and International [cite: 3, 4]. In the fiscal year ended June 30, 2026, Clorox generated $6.72 billion in net sales, reflecting its immense scale in the consumer packaged goods sector [cite: 5, 6].
The company's core product suite is highly diversified, ranging from retail household essentials to professional-grade sanitization systems. The Health and Wellness segment encompasses laundry additives, home care disinfecting products (such as flagship Clorox bleach, Pine-Sol, and Scentiva), professional cleaning systems (CloroxPro), and professional skin hygiene solutions under the newly integrated Purell brand [cite: 3, 7]. The Household segment consists of bags and wraps (Glad), grilling products (Kingsford charcoal), and cat litter (Fresh Step, Scoop Away) [cite: 3]. The Lifestyle segment comprises retail water filtration (Brita), food products (Hidden Valley dressing), and natural personal care (Burt's Bees) [cite: 3, 8]. The International segment oversees sales of these brands outside the United States [cite: 4].
Clorox's primary customer base spans two distinct channels: mass retail and professional business-to-business (B2B) markets. In the retail channel, sales are highly consolidated, with mass merchandisers, warehouse clubs, grocery stores, and e-commerce platforms serving as major intermediaries [cite: 9]. Walmart and its affiliates represent the company's single largest customer, accounting for approximately 27% of consolidated net sales [cite: 10, 11]. In the professional channel, the company targets healthcare facilities, educational institutions, commercial offices, and hospitality venues [cite: 12, 13]. This channel was significantly strengthened by the April 1, 2026, acquisition of GOJO Industries, the maker of Purell, which distributes over 80% of its products through a vast B2B network [cite: 12, 13].
Customers consistently select Clorox products over generic and private-label alternatives due to deep brand equity, trust, and perceived value superiority [cite: 14]. In critical categories like surface disinfection and professional skin hygiene, buyers exhibit low risk tolerance, preferring established, clinically validated brands [cite: 14]. Clorox's strategic position is anchored by the fact that approximately 80% of its sales are generated by brands holding the number one or number two market share positions in their respective categories [cite: 1, 11]. This dominance is sustained by consumer-centered innovation and an integrated supply chain that ensures consistent retail shelf availability [cite: 15, 16].
The economic health of Clorox is driven by a portfolio of high-turnover household consumables requiring constant replenishment, supplemented by a structurally sticky B2B institutional business [cite: 12, 14]. The baseline organic growth is dictated by the velocity of products such as Clorox disinfecting wipes, Kingsford charcoal, Glad trash bags, and Fresh Step litter [cite: 3, 15]. Historically, the company has targeted a long-term sales growth rate of 3% to 5% annually [cite: 1, 17]. The strategic center of gravity has recently shifted with the integration of GOJO Industries, acquired on April 1, 2026, for a cash transaction value of $2.25 billion (implying a net purchase price of $1.92 billion after accounting for $330 million in expected tax benefits) [cite: 12, 13]. This acquisition, now operating as Clorox Purell, adds a powerful engine to the Health and Wellness segment, injecting nearly $800 million in recurring annual sales that have historically grown at a 5% three-year compound annual growth rate [cite: 13, 18].
Clorox holds a highly defensible competitive moat defined by several critical economic advantages. In the consumer space, its brand equity functions as a formidable entry barrier, with the "Clorox" trademark operating practically as a synonym for bleach and hard-surface sanitization [cite: 14]. In the professional B2B channel, the business model is protected by switching costs [cite: 12, 13]. Clorox Purell operates a highly lucrative "razor-and-blade" ecosystem, utilizing a global installed base of approximately 20 million proprietary electronic soap and hand sanitizer dispensers [cite: 12, 13]. Once hospitals, schools, or commercial properties physically install these dispensers throughout their facilities, they face high administrative, procurement, and labor costs to remove and replace them with competing hardware [cite: 12, 13]. This dynamic secures a highly visible, long-term stream of recurring high-margin refill revenue [cite: 12]. Furthermore, high regulatory barriers defend this moat [cite: 9]. Disinfecting agents and sanitizers intended for clinical environments require rigorous clearance from the Environmental Protection Agency (EPA) or Food and Drug Administration (FDA) [cite: 9, 13]. The approval process typically demands 12 to 36 months of testing and capital outlays ranging from $0.5 million to $5.0 million per SKU, preventing rapid, low-cost duplication by generic market entrants [cite: 9].
The addressable market opportunity is supported by permanent global shifts in public health standards [cite: 19]. The North American cleaning products market was estimated at $84.4 billion in 2025 and is projected to expand to $88.7 billion in 2026, ultimately scaling to $148.5 billion by 2035 at a compound annual growth rate of 5.9% [cite: 20]. Within this broader market, Procter & Gamble is the dominant premium market leader, commanding a 35% market share in 2025 [cite: 20]. The top five players, comprising Procter & Gamble, Church & Dwight, Clorox, Reckitt Benckiser, and SC Johnson, collectively held a market share of 55% in 2025 [cite: 20]. This leaves a substantial 45% of the market highly fragmented, representing a long-term consolidation opportunity for Clorox’s scale [cite: 20]. Additionally, adjacent niches such as the global air care chemicals market are projected to grow from $5.4 billion in 2026 to $8.5 billion by 2036, displaying a CAGR of 4.6% [cite: 21].
In terms of positioning, Clorox resides in the premium tier, relying on marketing investments and consumer-obsessed product improvements to justify its price premium relative to value players like Church & Dwight and private-label alternatives [cite: 9, 14]. Private-label offerings represent the most dangerous price threat, undercutting branded bleach and trash bags by 15% to 30% [cite: 9]. While private labels have captured up to 25% of regional laundry detergent and commoditized household volumes [cite: 22], Clorox is holding ground by systematically reclaiming about 90% of the market share it temporarily lost during its 2023 cyberattack [cite: 15, 23]. The addition of Purell is growth-accretive, adding an estimated 30 to 50 basis points to Clorox's overall organic sales growth profile while expanding its higher-margin commercial footprint [cite: 24].
The Clorox Company reported its fourth-quarter and full fiscal year 2026 results on August 3, 2026 [cite: 4, 5].
During the fourth quarter of fiscal 2026 (ended June 30, 2026), net sales declined 2% year-over-year to $1.95 billion [cite: 4, 5]. However, this top-line result beat the consensus Wall Street projection of $1.91 billion [cite: 25, 26]. The newly integrated GOJO acquisition contributed approximately 10 percentage points of growth [cite: 4, 26]. Organic sales for the quarter fell 13%, primarily driven by lapping elevated incremental shipments related to the ERP transition in the prior-year quarter, which created a steep 13.5-point volume comparison drag [cite: 4, 26].
The gross margin for the quarter fell by 520 basis points to 41.3%, down from 46.5% in the prior year [cite: 4, 26]. This contraction was driven by lower volume, the accounting impact of the GOJO inventory step-up, higher commodity costs, and manufacturing and logistics inflation [cite: 4, 26]. The ERP-related shipment comparison and the GOJO inventory step-up each reduced gross margin by approximately 150 basis points [cite: 4, 26]. Diluted net earnings per share under GAAP plummeted 50% to $1.34 from $2.68 [cite: 4, 5]. Non-GAAP adjusted EPS declined 42% to $1.66 from $2.87 [cite: 4, 5]. However, this bottom-line performance marginally exceeded analyst expectations, beating the consensus estimate of $1.65 by one cent [cite: 5, 26].
For the full fiscal year 2026, Clorox reported net sales of $6.72 billion, representing a 5% decline compared to fiscal year 2025 [cite: 5, 6]. Organic sales declined 8%, with the ERP shipment comparison timing acting as a 7.5-point headwind [cite: 5, 6]. Full-year GAAP gross margin declined 290 basis points to 42.3%, primarily driven by lower volume and manufacturing cost headwinds [cite: 5, 6]. Diluted GAAP EPS fell 26% to $4.81 from $6.52, while non-GAAP adjusted EPS fell 28% to $5.53 from $7.72, incorporating a $0.90 per share headwind from ERP-related shipment timing [cite: 5, 6]. Cash provided by operations declined 38% to $612 million, down from $981 million in the prior year, directly impacted by the cash payout associated with the Glad joint venture agreement termination [cite: 5, 6]. On an adjusted basis, free cash flow was resilient at $881 million, representing 13.1% of net sales [cite: 5, 6].
The segments performed as follows during the fourth quarter of fiscal 2026:
| Segment | Net Sales Change (GAAP) | Organic Sales Change | Segment Adjusted EBIT Change | Key Performance Drivers |
|---|---|---|---|---|
| Health and Wellness | +16% [cite: 4] | -12% [cite: 4] | -15% [cite: 4] | Growth driven by a 28-point contribution from GOJO; margin impacted by advertising and lapping ERP shipments [cite: 4]. |
| Household | -18% [cite: 4] | -18% (Implied) | -56% [cite: 4] | Volume decline of 16% due to lapping ERP shipments and Q3 advance shipping of grilling and litter [cite: 4]. |
| Lifestyle | -17% [cite: 4] | -17% (Implied) | -60% [cite: 4] | Volume drop of 14% driven by lapping elevated prior-year ERP shipments [cite: 4]. |
| International | +4% [cite: 4] | +1% [cite: 4] | +17% [cite: 4] | Benefit from favorable foreign exchange rates and structured cost-saving initiatives [cite: 4]. |
During the August 3, 2026 announcement, Clorox issued an upbeat guidance outlook for fiscal year 2027 [cite: 5, 26]. Management projected net sales to rise 13% to 14% year-over-year, driven by a 9.5-point annualized benefit from the GOJO acquisition [cite: 5, 26]. Organic sales are guided to increase by 3.5% to 4.5% as the company laps the ERP-related inventory drawdowns from the prior year [cite: 5, 26]. Adjusted EPS is guided to a range of $5.70 to $6.00, with a midpoint of $5.85 that exceeded the analyst consensus estimate of $5.52 [cite: 5, 26].
This represents a major operational stabilization compared to the previous guidance cycle on April 30, 2026, when Clorox slashed its full-year guidance due to severe cost pressures, adjusting its full-year adjusted EPS guidance from a previous range of $5.95–$6.30 down to a range of $5.45–$5.65 [cite: 27, 28]. Lapping this lower baseline provides Clorox with strong momentum into FY27 [cite: 26].
Chair and CEO Linda Rendle highlighted that the majority of the core business is performing at or above expectations, with the global health and hygiene portfolio now representing more than half of the company's total net sales [cite: 16]. Rendle emphasized that the business is focused on transitioning from building foundational systems to extracting the financial benefits of its ERP overhaul and GOJO procurement synergies [cite: 16].
The options market had anticipated an implied volatility move of 7.03% heading into the print, but the actual market reaction was moderately positive [cite: 26, 29]. The shares rose approximately 1% in post-market trading immediately following the release [cite: 26]. This price action followed a period of intense skepticism [cite: 30]. On July 28, 2026, Jefferies downgraded the stock from Buy to Hold and cut its price target to $98 from $125, citing sluggish volume trends and execution risks surrounding the upcoming CEO transition [cite: 25, 30]. The company's upbeat FY27 guidance midpoint of $5.85 acts as a stabilizing force to rebuild confidence [cite: 26].
The primary long-term valuation driver is the company's ability to defend its gross margin while stabilizing volumes [cite: 29]. Over the past five years, top-line growth has been highly volatile due to external shocks, including a major cyberattack in 2023 and the subsequent ERP system cutover, leading to a negative five-year sales growth rate of -2.11% [cite: 31, 32]. However, the underlying cash-generation capacity remains strong, supported by high brand density and a low capital-expenditure requirement (typically 2% to 3% of sales) [cite: 33]. The current trailing valuation of 15.5x P/E sits well below the historical five-year average of 23.4x, and a PEG ratio of 0.23 indicates that the market has discounted the stock due to temporary operational integration issues rather than a permanent loss of competitive advantage [cite: 32, 34].
Evaluating Clorox's investment profile requires a detailed understanding of its risk exposure across multiple operational, competitive, and macroeconomic layers.
The five-year scenario model projects the total return of Clorox Company through Fiscal Year 2031. The current share price of $95.53 USD as of July 31, 2026, serves as the baseline for all returns [cite: 46].
The Base Case assumes the company achieves operational stabilization under a newly appointed CEO [cite: 35]. The U.S. ERP transition is fully optimized, allowing for smoother customer shipments and localized supply chains [cite: 5]. Top-line growth matches the midpoint of the FY27 guided range (+13.5%) [cite: 5, 26] and subsequently grows at a 3.5% CAGR, in line with the company's long-term organic growth target of 3% to 5% [cite: 1, 17]. The gross margin expands toward 44.5% as ERP transition costs dissolve and $50 million in annualized GOJO cost synergies are successfully realized [cite: 12, 19, 45]. The net profit margin stabilizes at 11.5%, generating $1.007 billion USD in annual earnings [cite: 32]. Strategic share repurchases reduce the outstanding diluted share count to 118.0 million [cite: 47]. With restored operational performance, the stock trades at 18.0x P/E, which is a conservative discount to its five-year historical average of 23.4x [cite: 32].
* Year 5 Revenue: $8.76 Billion USD [cite: 5, 17, 26]
* Operating Margin / Earnings: 11.5% Net Margin / $1.007 Billion USD Net Income [cite: 32]
* Diluted Share Count: 118.0 Million [cite: 47]
* Implied Exit EPS: $8.53 USD [cite: 5, 6]
* Exit Multiple: 18.0x P/E [cite: 32]
* Projected Year 5 Share Price: $153.54 USD [cite: 46]
* Cumulative Dividends (5-Year): $25.00 USD [cite: 48]
* 5-Year Total Return / Annualized Return: 86.9% / 13.3% [cite: 46]
The High Case assumes a rapid and highly successful integration of GOJO [cite: 7]. The company leverages its B2B distribution network to expand Purell into international markets and retail club channels, generating cost synergies of $75 million, which exceeds initial targets [cite: 12, 13]. Revenue growth matches the high end of FY27 guidance (+14.0%) [cite: 5, 26] and subsequently compounds at a 5.0% CAGR through FY31 [cite: 17]. Strong pricing power and favorable raw material costs allow gross margins to expand toward 47%, leading to a 13.0% net profit margin [cite: 12, 32]. Robust free cash flow generation enables accelerated share repurchases, shrinking the share count to 115.0 million [cite: 47, 49]. The P/E multiple expands to 22.0x as the market re-rates the stock as a premium defensive compounder [cite: 32].
* Year 5 Revenue: $9.31 Billion USD [cite: 5, 17, 26]
* Operating Margin / Earnings: 13.0% Net Margin / $1.210 Billion USD Net Income [cite: 12, 32]
* Diluted Share Count: 115.0 Million [cite: 47]
* Implied Exit EPS: $10.52 USD [cite: 5, 6]
* Exit Multiple: 22.0x P/E [cite: 32]
* Projected Year 5 Share Price: $231.44 USD [cite: 46]
* Cumulative Dividends (5-Year): $26.00 USD [cite: 48]
* 5-Year Total Return / Annualized Return: 169.5% / 21.9% [cite: 46]
The Low Case assumes a highly challenging operational backdrop. The CEO transition is protracted, and private label market share gains persist, causing severe price compression and volume erosion [cite: 9, 38]. GOJO cost synergies are not realized, and packaging regulations inflate SG&A expenses [cite: 12, 41]. Revenue grows at the low end of FY27 guidance (+13.0%) [cite: 5, 26] and subsequently stagnates at a 1.5% CAGR [cite: 50]. Net margins contract to 8.5% due to packaging cost inflation, commodity price spikes, and elevated debt-servicing requirements on its $5.1 billion debt load [cite: 28]. Share counts dilute slightly to 121.5 million due to stock-based compensation offsetting restricted buybacks [cite: 47]. The P/E multiple de-rates to 14.0x [cite: 32].
* Year 5 Revenue: $8.07 Billion USD [cite: 5, 26, 50]
* Operating Margin / Earnings: 8.5% Net Margin / $686 Million USD Net Income [cite: 32]
* Diluted Share Count: 121.5 Million [cite: 47]
* Implied Exit EPS: $5.65 USD [cite: 5, 6]
* Exit Multiple: 14.0x P/E [cite: 32]
* Projected Year 5 Share Price: $79.10 USD [cite: 46]
* Cumulative Dividends (5-Year): $24.00 USD [cite: 48]
* 5-Year Total Return / Annualized Return: 7.9% / 1.5% [cite: 46]
The five-year share price trajectory is calculated under each scenario, assuming a linear progression of earnings and margin normalization over the five-year modeling period:
| Scenario | Year 0 Share Price | Year 1 Share Price | Year 2 Share Price | Year 3 Share Price | Year 4 Share Price | Year 5 Share Price |
|---|---|---|---|---|---|---|
| High Case | $95.53 USD [cite: 46] | $115.00 USD | $138.00 USD | $165.00 USD | $197.00 USD | $231.44 USD |
| Base Case | $95.53 USD [cite: 46] | $105.00 USD | $115.00 USD | $127.00 USD | $140.00 USD | $153.54 USD |
| Low Case | $95.53 USD [cite: 46] | $92.00 USD | $89.00 USD | $86.00 USD | $82.00 USD | $79.10 USD |
By weighting the projected future share prices by their subjective probabilities (60% Base, 20% High, 20% Low), the probability-weighted target is calculated at $154.23 USD. This target implies a significant potential upside from the baseline price of $95.53 USD, primarily driven by core margin stabilization and the integration of GOJO's cash flows [cite: 28, 46].
| Scenario | Revenue / key scale metric in Year 5 | Margin / earnings assumption | Valuation multiple assumption | Current share price | Implied future share price | 5-year total return | Annualized return | Probability |
|---|---|---|---|---|---|---|---|---|
| High Case | $9.31B USD [cite: 5, 17, 26] | 13.0% / $1.210B USD [cite: 12, 32] | 22.0x P/E [cite: 32] | $95.53 USD [cite: 46] | $231.44 USD [cite: 46] | 169.5% | 21.9% | 20% |
| Base Case | $8.76B USD [cite: 5, 17, 26] | 11.5% / $1.007B USD [cite: 32] | 18.0x P/E [cite: 32] | $95.53 USD [cite: 46] | $153.54 USD [cite: 46] | 86.9% | 13.3% | 60% |
| Low Case | $8.07B USD [cite: 5, 26, 50] | 8.5% / $686M USD [cite: 32] | 14.0x P/E [cite: 32] | $95.53 USD [cite: 46] | $79.10 USD [cite: 46] | 7.9% | 1.5% | 20% |
ASYMMETRIC RECOVERY PROFILE
To evaluate the operational health and long-term positioning of The Clorox Company, the following qualitative matrix assesses ten critical dimensions of the business on a scale of 1–10:
The qualitative scorecard reveals a business possessing structurally sound brands and robust market share [cite: 1, 11], but currently constrained by balance sheet leverage and near-term leadership uncertainty [cite: 38, 43]. This analysis does not constitute financial advice or an investment recommendation.
STABILIZING CORE ASSETS
The investment profile of Clorox Company is defined by a dichotomy between temporary operational headwinds and underlying brand strength. Structurally, the business has successfully completed its painful multi-year U.S. ERP implementation and fully recovered the market share lost during the devastating 2023 cyberattack [cite: 15, 23]. The strategic acquisition of GOJO (Purell) has evolved the company's portfolio toward higher-margin, highly recurring B2B professional channels, backed by a massive footprint of 20 million installed refilling stations [cite: 12, 13].
Financially, the company's latest Q4 and FY26 results demonstrate that while margins remain pressured by commodity costs and acquisition integration expenditures, the business has successfully defended its top and bottom line, beating consensus expectations [cite: 4, 26]. More importantly, management's forward FY27 adjusted EPS guidance of $5.70 to $6.00 and revenue growth projections of 13% to 14% indicate a significant operational inflection point [cite: 5, 26].
The primary catalysts for valuation normalization over the next 12 to 24 months include:
1. The successful appointment of a seasoned consumer-packaged-goods CEO to succeed Linda Rendle, resolving leadership uncertainty [cite: 35, 38].
2. The realization of the guided $50 million in run-rate cost synergies from the GOJO integration [cite: 12, 19].
3. The deleveraging of the balance sheet, using strong organic free cash flow to reduce net debt-to-EBITDA back below 3.0x [cite: 28, 43].
The main risk to this thesis lies in raw material price volatility, particularly a sustained rise in petrochemical costs, and pricing pressure from private labels [cite: 9, 28]. However, trading at approximately 15.5x P/E—a major discount to its historical average of 23.4x and peer Church & Dwight at 32x—and offering a secure, recently raised dividend yield of 5.19%, the equity appears structurally undervalued [cite: 32, 48, 56, 57]. The risk-reward ratio strongly favors patient investors as operational normalization takes hold [cite: 33]. This analysis does not constitute financial advice or an investment recommendation.
UNDERVALUED STRUCTURAL TURNAROUND
Clorox's stock price action indicates a persistent technical downtrend, with the share price of $95.53 USD trading well below its declining 200-day simple moving average of $104.24 USD [cite: 46, 58, 59]. Short-term technical indicators, including an RSI of 37 to 50 and a negative MACD, suggest a neutral-to-oversold condition, with the stock stabilizing near its 52-week support floor of $84.70 USD [cite: 46, 60, 61]. The immediate short-term outlook is expected to show technical stabilization; management's upbeat FY27 guidance beat and the quarterly dividend increase to $1.25 per share provide a reliable fundamental floor to reverse negative momentum [cite: 5, 26, 48]. This analysis does not constitute financial advice or an investment recommendation.
STABILIZING AT SUPPORT
View Clorox Company (The) (CLX) stock page
Loading the interactive version of this report…